Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors

NCT00902122 is registered in ClinicalTrials.gov with Shenzhen SiBiono GeneTech Co.,Ltd as lead sponsor.

NCT NCT00902122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00902122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors
Lead sponsor
Shenzhen SiBiono GeneTech Co.,Ltd
Phase
Phase 4
Overall status
Unknown status
Start date
May 31, 2009
Completion date
August 31, 2012
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant thyroid tumors